SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 12/11/2017 4:01:19 PM - Followers: 733 - Board type: Free - Posts Today: 279

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
PostSubject
#207221  Sticky Note Re B-OM Ph2 topline: A Lead-Off Stand-Up Double slcimmuno 12/11/17 08:36:46 AM
#205289  Sticky Note Due diligence: Innovation Pharmaceuticals Inc. (IPIX) BooDog 11/30/17 06:20:08 AM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#206868   Thanks and thanks! :-D LilKahuna 12/08/17 08:37:45 AM
#206867   Thanks to the both of you, can't wait LilyGDog 12/08/17 08:36:31 AM
#206866   here's the problem with all these $20-50 pie MXAMDUD 12/08/17 08:35:38 AM
#206865   Few far and between, but I have seen BooDog 12/08/17 08:34:02 AM
#206864   FINRA determines that an extraordinary event has tryz 12/08/17 08:25:22 AM
#206863   as usual, you would be correct. TheHound 12/08/17 08:10:20 AM
#206862   My understanding is there are no trading halts LilKahuna 12/08/17 08:07:31 AM
#206861   I think today we close "GREEN" on above On Rocket 12/08/17 08:06:23 AM
#206860   "Have you ever heard of SEC Form 4 loanranger 12/08/17 08:06:04 AM
#206857   tryz, LilyGDog 12/08/17 07:51:55 AM
#206856   I am anticipating and been waiting patiently for tryz 12/08/17 07:39:55 AM
#206855   New shareholders aren’t inherently stupid. Let them reason TheDane 12/08/17 07:38:31 AM
#206854   I shorted at .68. Covering at 2.00. things septmike09 12/08/17 07:36:59 AM
#206853   So, we can finally put this issue to TheDane 12/08/17 07:36:48 AM
#206852   There is no such thing as a "delayed" septmike09 12/08/17 07:33:33 AM
#206851   IPIX is flying under the radar, but wait georgejjl 12/08/17 07:27:31 AM
#206850   Agree 100% cabel......Scrounged up some dry powder yesterday tryz 12/08/17 07:27:01 AM
#206849   knowing mgmt, it will be delayed untilQ2 2018 MXAMDUD 12/08/17 07:21:00 AM
#206848   I think we are no longer trading days cabel 12/08/17 07:16:13 AM
#206847   It is about time for the OM results. Tension pix 12/08/17 05:35:56 AM
#206846   Its hard for me to imagine that you BIzzy 12/08/17 02:18:22 AM
#206845   The only reason I am ever compelled to cybermich 12/08/17 01:47:45 AM
#206844   That’s a great point. I hope everyone realizes sox040713 12/08/17 12:52:50 AM
#206842  Restored * * $IPIX Video Chart 12-07-17 * * ClayTrader 12/07/17 10:12:15 PM
#206841   That's the beauty of being long, low capital Williamsc 12/07/17 10:11:22 PM
#206840   “With all patients having received treatment, we look georgejjl 12/07/17 09:59:57 PM
#206839   Yes, happy days! I have long $hares so TheDane 12/07/17 09:47:37 PM
#206838   At least were no longer talking tax losses. Williamsc 12/07/17 09:45:59 PM
#206837   Ditto. When I don’t like what’s repeatedly posted TheDane 12/07/17 09:30:44 PM
#206836   October 26, 2017 Innovation Pharmaceuticals Aims to Develop First Matagordaville 12/07/17 09:20:09 PM
#206835   November 16, 2017 Innovation Pharmaceuticals Offers Perspectives on Brilacidin Matagordaville 12/07/17 09:18:04 PM
#206834   If true we now have 40 million shares Blue Fin 12/07/17 08:58:51 PM
#206833   Let’s compare IPIX’s numbers to Apple’s. Anybody F1ash 12/07/17 08:48:34 PM
#206832   Yada yada yada.Finra's statements are obtuse at best keltoi 12/07/17 08:48:08 PM
#206831   New investors, the statement "42% of today's volume sox040713 12/07/17 08:34:25 PM
#206830   perhaps you would like to make an inference To infinity and beyond! 12/07/17 08:33:22 PM
#206829   Sad how some will come on and blatantly Williamsc 12/07/17 08:21:25 PM
#206828   Not that $IPIX has some ground breaking potentially BooDog 12/07/17 08:19:14 PM
#206827   More Nonsense!!!!! Have you ever heard of DaysOnTheBeach 12/07/17 08:10:24 PM
#206826   Nonsense!!! It's Aspire that's made shareholder wealth possible!!! DaysOnTheBeach 12/07/17 08:05:04 PM
#206825   FINRA short sales of IPIX AlanC 12/07/17 08:01:21 PM
#206824   One of many, but what I look at Williamsc 12/07/17 07:59:49 PM
#206823   this is just 1 application untohim 12/07/17 07:56:41 PM
#206822   I agree. B for OM is an industry Williamsc 12/07/17 07:54:29 PM
#206821   OH! it will be inconsequential alright! untohim 12/07/17 07:46:31 PM
#206820   Wait and see. Great OM results will scottsmith 12/07/17 07:40:12 PM
#206819   idiotic supposition drawn from thin air to fit BIzzy 12/07/17 07:39:42 PM
#206818   You sure about that smith? :) untohim 12/07/17 07:29:59 PM
#206817   Today was Day 8 since the Cox Report. scottsmith 12/07/17 07:24:34 PM
#206816   Data expected Monday. Tomorrow will be up. sixmilliondollarbios 12/07/17 07:24:09 PM
PostSubject